COVID-19大流行期间植入式心律转复除颤器患者的室性心律失常负荷变化
该多中心观察性队列研究通过远程监测评估美国COVID-19大流行100天内20个中心5963例ICD患者的室性心律失常负荷。结果显示室性心律失常负荷进行性下降,需器械治疗的室性心律失常减少32%,高COVID-19发病率州患者发生室性心律失常的比例降低39%。
要点
- COVID-19期间ICD患者需器械治疗的室性心律失常较对照期减少32%。
- 高COVID-19发病率州患者室性心律失常比例较低发病率州显著降低(OR 0.61)。
- 室性心律失常负荷随COVID-19进展进行性下降(P<0.001)。
核心结论
- COVID-19期间需器械治疗的室性心律失常减少32%,与社交隔离措施 coincide。
- 高COVID-19发病率州患者室性心律失常比例降低39%。
- 真实生活应激因素可能影响ICD患者的室性心律失常负荷。
研究设计与样本
- 多中心、观察性、队列研究,覆盖美国13个州20个中心。
- COVID-19大流行期间100天,通过远程监测评估ICD患者室性心律失常。
- 对照包括2019年末100天对照期和2019年初季节性对照期。
- COVID-19期间5963例ICD患者接受远程监测。
主要发现
- COVID-19期间室性心律失常负荷进行性下降(P<0.001)。
- 高COVID-19发病率州患者室性心律失常比例显著低于低发病率州(OR 0.61,95%CI 0.54-0.69,P<0.001)。
- 同时接受COVID-19期和对照期远程监测的2458例患者中,COVID-19期间室性心律失常显著减少(IRR 0.68,95%CI 0.58-0.79,P<0.001)。
- 同时接受COVID-19期和季节性对照期监测的1719例患者中差异持续存在(IRR 0.69,95%CI 0.56-0.85,P<0.001)。
临床怎么用
- COVID-19大流行期间ICD患者室性心律失常负荷下降,提示真实生活应激因素可能影响心律失常发生。
- 远程监测可用于评估特殊时期ICD患者的室性心律失常负荷变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Our objective was to determine the ventricular arrhythmia burden in implantable cardioverter-defibrillator (ICD) patients during COVID-19. METHODS AND RESULTS: In this multicentre, observational, cohort study over a 100-day period during the COVID-19 pandemic in the USA, we assessed ventricular arrhythmias in ICD patients from 20 centres in 13 states, via remote monitoring. Comparison was via a 100-day control period (late 2019) and seasonal control period (early 2019). The primary outcome was the impact of COVID-19 on ventricular arrhythmia burden. The secondary outcome was correlation with COVID-19 incidence. During the COVID-19 period, 5963 ICD patients underwent remote monitoring, with 16 942 episodes of treated ventricular arrhythmias (2.8 events per 100 patient-days). Ventricular arrhythmia burden progressively declined during COVID-19 (P < 0.001). The proportion of patients with ventricular arrhythmias amongst the high COVID-19 incidence states was significantly reduced compared with those in low incidence states [odds ratio 0.61, 95% confidence interval (CI) 0.54-0.69, P < 0.001]. Comparing patients remotely monitored during both COVID-19 and control periods (n = 2458), significantly fewer ventricular arrhythmias occurred during COVID-19 [incident rate ratio (IRR) 0.68, 95% CI 0.58-0.79, P < 0.001]. This difference persisted when comparing the 1719 patients monitored during both the COVID-19 and seasonal control periods (IRR 0.69, 95% CI 0.56-0.85, P < 0.001). CONCLUSIONS: During COVID-19, there was a 32% reduction in ventricular arrhythmias needing device therapies, coinciding with measures of social isolation. There was a 39% reduction in the proportion of patients with ventricular arrhythmias in states with higher COVID-19 incidence. These findings highlight the potential role of real-life stressors in ventricular arrhythmia burden in individuals with ICDs. TRIAL REGISTRATION: Australian New Zealand Clinical Trial Registry; URL: https://www.anzctr.org.au/; Unique Identifier: ACTRN12620000641998.
引用
- O'Shea CJ, Thomas G, Middeldorp ME, et al. Ventricular arrhythmia burden during the coronavirus disease 2019 (COVID-19) pandemic. Eur Heart J. 2021. PMID: 33321517. doi:10.1093/eurheartj/ehaa893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。